The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 140.00
Bid: 135.00
Ask: 145.00
Change: 12.50 (9.80%)
Spread: 10.00 (7.407%)
Open: 127.50
High: 140.00
Low: 127.50
Prev. Close: 127.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Aug 2019 09:33

RNS Number : 4760J
Faron Pharmaceuticals Oy
19 August 2019
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Faron Pharmaceuticals Ltd

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Timo Syrjälä

City and country of registered office (if applicable)

 

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

05.08.2019

6. Date on which issuer notified (DD/MM/YYYY):

15.08.2019

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

14.36%

 

14.36%

38.175.734

Position of previous notification (if

applicable)

13.11%

 

13.11%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

FI4000153309

2.205.025

3.275.350

5.78%

8.58%

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

5.480.375

14.36%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

          

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Timo Syrjälä (Direct)

5.78%

5.78%

Acme Investments SPF Sarl (Indirect)

8.58%

 

8.58%

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi  Threshold announced in company stock market release 5.8.2019

 

     

 

Place of completion

Lausanne

Date of completion

15/08/2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFMGMRRLGGLZG
Date   Source Headline
22nd Jun 20217:00 amRNSUpdated corporate presentation
14th Jun 202111:05 amRNSSecond Price Monitoring Extn
14th Jun 202111:00 amRNSPrice Monitoring Extension
14th Jun 20217:00 amRNSBexmarilimab granted key US patent
3rd Jun 20217:00 amRNSBexmarilimab results published in CCR
17th May 20217:00 amRNSBexmarilimab shows promising anti-tumour activity
14th May 20217:00 amRNSUS rights to patent related to Traumakine
10th May 20212:30 pmRNSHolding(s) in Company
29th Apr 202112:45 pmRNSGrant of options
23rd Apr 20211:45 pmRNSBoard Change
23rd Apr 20211:45 pmRNSResult of AGM
29th Mar 20217:00 amRNSAppointment of a Broker
25th Mar 20217:45 amRNSExercise of Options
25th Mar 20217:30 amRNSNotice of Faron Pharmaceuticals Ltd’s AGM
25th Mar 20217:15 amRNSFaron´s Annual Report 2020 published
25th Mar 20217:00 amRNSFinancial statement January 1 to December 31 2020
22nd Mar 20217:00 amRNSBexmarilimab (Clevegen) development update
11th Mar 20217:00 amRNSFaron to Present at Oppenheimer Conference
2nd Mar 20217:00 amRNSFaron to Present at H.C. Wainwright Conference
25th Feb 20217:00 amRNSNotice of Full-Year Results and Annual Report
17th Feb 20214:30 pmRNSHolding(s) in Company
12th Feb 20213:00 pmRNSRegistration of Placing Shares
12th Feb 20217:00 amRNSResults of Placing and Issue Price
11th Feb 20214:30 pmRNSProposed Issue and Placing of Shares
26th Jan 20217:00 amRNSUpdate on TRAUMAKINE development
20th Jan 20212:06 pmRNSSecond Price Monitoring Extn
20th Jan 20212:01 pmRNSPrice Monitoring Extension
20th Jan 20217:00 amRNSBexmarilimab (Clevegen) development update
18th Jan 20212:05 pmRNSSecond Price Monitoring Extn
18th Jan 20212:00 pmRNSPrice Monitoring Extension
18th Jan 202111:06 amRNSSecond Price Monitoring Extn
18th Jan 202111:01 amRNSPrice Monitoring Extension
18th Jan 20217:00 amRNSUS Department of Defense to support TRAUMAKINE
4th Jan 20217:00 amRNSFaron to Present at H.C. Wainwright
21st Dec 20207:00 amRNSFaron’s financial calendar for 2021
10th Dec 20207:00 amRNSPresents at ESMO Immuno-Oncology Virtual Congress
23rd Nov 20207:30 amRNSTo Participate in Upcoming Investor Conferences
23rd Nov 20207:00 amRNSBexmarilimab (Clevegen) development update
20th Nov 20207:00 amRNSIssue of Equity
16th Oct 202011:35 amRNSFirst Results from WHO Solidarity Trial
14th Oct 20202:15 pmRNSGrant of options
30th Sep 20209:45 amRNSHolding(s) in Company
24th Sep 20207:15 amRNSExercise of options
24th Sep 20207:00 amRNSHalf-year Report
18th Sep 20207:00 amRNSMATINS trial data presented at ESMO
9th Sep 202012:00 pmRNSFaron to Present at H.C. Wainwright Conference
27th Aug 20207:00 amRNSNotice of Half-Year Report
18th Aug 20207:00 amRNSTraumakine Update
17th Aug 20204:41 pmRNSSecond Price Monitoring Extn
17th Aug 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.